Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

PROCEDURES INVOLVED:

Participants will be enrolled for an estimated 96 weeks: Measurements will be requested every 24 weeks on a specifically designed survey instrument for participants. Participants will be asked to report medication dosing, adherence to medicine, tolerability, etc. as per Table 1. It is planned that each participant will be enrolled for 96 weeks (screening visit, baseline visit and four follow up visits at 24, 48, 72, and 96 weeks respectively) and would receive Ublituximab on an every 24 week schedule through regular clinical care. Notably, insurance may cover Ublituximab at an every 26 week schedule in which case accommodations will be made to have each study visit at q24-26 week intervals.

Participants will be contacted and interviewed every 24 weeks to ensure study procedures are going as planned, verify data reported on medication and MS disease history, and ensure study procedures are operating smoothly. Participants who do not complete the surveys within 7 days of the scheduled timing will be contacted by a study coordinator by phone up to 3 times. Participants will also be asked to report any medication changes, dose changes, or discontinuations if they occur at any point between study visits.

Participants will be enrolled until a total of 40 individual participants are reached. All scheduled events listed here will be part of the study and not part of routine clinical care. Study screening will continue until 40 participants are fully enrolled. Once 40 participants are enrolled, additional patients will not be screened or enrolled regardless of whether existing participants drop out of the study or are lost to follow-up. Five screen failures are estimated based on our study team's experience with ENHANCE (Ublituximab clinical trial). Once a participant is enrolled, the study will follow an intention to treat analysis.

Inclusion criteria

• Meet 2024 Criteria for Multiple Sclerosis (Montalban et al.) as confirmed by a neurologist; Includes dissemination in space in two of five topographies (with optic nerve included) and/or biomarker evidence such as positive cerebrospinal fluid oligoclonal bands, elevated kappa free light chains, at least six central vein lesions, or at least one paramagnetic rim lesion;
• Adult age 18-70 years,
• EDSS <2.5,
• Able to provide individual informed consent,
• MRI brain available to confirm the diagnosis of MS with fewer than 10 demyelinating lesions,
• Diagnosis of MS within the past <5 years,
• Planning to start Ublituximab for the treatment of relapsing MS,

Exclusion criteria

• Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
• Prior exposure to other B-cell depleting agent including Ocrelizumab, Rituximab, Ofatumumab, and Inebilizumab.
• Current clinical trial participant,
• Unable to speak a language for which translation can be found in the hospital system,
• Unclear documentation of MS diagnosis or prior or current MS treatment,
• Recent major surgical procedure in the past 6 months,
• History of life-threatening infusion reaction on Ublituximab or prior anti-CD20 therapy
• Active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests.
• Receipt of any live of live-attenuated vaccines within 4 weeks prior to first drug product administration
• Moribund status,
• Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, etc.),
• Unwilling to undergo blood draws,
• Unable to access Ublituximab through clinical coverage throughout the full 96-week treatment study period,
• Unable to complete the study activities for any reason as deemed by the study investigator.